CARDIOTEC
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDIOTEC is an injectable diagnostic agent approved in 1990 by Bracco, a diagnostic imaging company. The specific mechanism of action and clinical indication are not publicly detailed in available data, but the injectable formulation suggests use in cardiology imaging or therapeutic applications. This product represents a legacy pharmaceutical asset with over three decades of market presence.
LOE Approaching
With LOE approaching and competitive pressure at 30%, the brand team faces market contraction; headcount may shift toward transition planning or divestiture.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CARDIOTEC currently shows zero linked job postings, reflecting its mature LOE-approaching status. Career opportunities are limited to defensive commercial roles (sales, brand management) with minimal growth trajectory or new role creation.
Brand ManagerSales Representative
Worked on CARDIOTEC at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.